Advertisement

Endokarditis

Chapter
  • 1.5k Downloads

Zusammenfassung

Vor Beginn der Arä des therapeutischen Einsatzes von Antibiotika verlief eine infektiöse, bakterielle Endokarditis fast immer letal. Trotz großer diagnostischer und therapeutischer Fortschritte bleibt die Prognose einer Endokarditis auch heute noch schwerwiegend und ist nach wie vor mit beträchtlicher Morbidität und Letalität verbunden. Eine herzchirurgische prothetische Versorgung ist in etwa der Hälfte aller Fälle erforderlich. Rezente Guidelines diverser Fachgesellschaften erleichtern durch evidenz-basierte Empfehlungen die Betreuung von Patienten mit Endokarditis, allerdings fallen zunehmend mehr Patienten durch Komorbiditäten, Kontraindikationen für operative Versorgung, Alter und andere Aspekte aus dem Rahmen, der in Guidelines vorgegeben werden kann. Diese Zusammenstellung soll nicht nur auf die aktuellen Guidelines Bezug nehmen, sondern auch unter Einbindung rezenter Literatur zur Lösung klinischer Problemstellungen beitragen.

Literatur

  1. Avery LM, Felberbaum CB, Hasan M (2018) Ciprofloxacin for the treatment of Cardiobacter hominis prosthetic valve endocarditis. IDCases 11:77–79CrossRefGoogle Scholar
  2. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association, Infectious Diseases Society of America et al (2005) Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:e394–e434CrossRefGoogle Scholar
  3. Cherubin CE, Sapira JD (1993) The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later. Ann Intern Med 119:1017–1028CrossRefGoogle Scholar
  4. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, ICE Investigators et al (2007) The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J 154:1086–1094CrossRefGoogle Scholar
  5. Durack DT, Lukes AS, Bright DK (1994) New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 96:200–209CrossRefGoogle Scholar
  6. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W (2001) Fungal endocarditis: evidence in the world literature, 1965–1995. Clin Infect Dis 32:50–62CrossRefGoogle Scholar
  7. Feuchtner GM, Stolzmann P, Dichtl W, Schertler T, Bonatti J, Scheffel H et al (2009) Multislice computed tomography in infective endocarditis: comparison with transesophageal echocardiography and intraoperative findings. J Am Coll Cardiol 53:436–444CrossRefGoogle Scholar
  8. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, S. aureus Endocarditis and Bacteremia Study Group et al (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653–665CrossRefGoogle Scholar
  9. Friedland IR, McCracken GH Jr (1994) Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 331:377–382CrossRefGoogle Scholar
  10. Gavaldà J, Len O, Miró JM, Muñoz P, Montejo M, Alarcón A et al (2007) Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 146:574–579CrossRefGoogle Scholar
  11. Graupner C, Vilacosta I, SanRomán J, Ronderos R, Sarriá C, Fernández C et al (2002) Periannular extension of infective endocarditis. J Am Coll Cardiol 39:1204–1211CrossRefGoogle Scholar
  12. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F et al (2015) 2015 ESC Guidelines for the management of infective endocarditis: the task force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36:3075–3128CrossRefGoogle Scholar
  13. Kahveci G, Bayrak F, Mutlu B, Bitigen A, Karaahmet T, Sonmez K et al (2007) Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with active infective endocarditis. Am J Cardiol 99:1429–1433CrossRefGoogle Scholar
  14. Lamas CC, Eykyn SJ (1997) Suggested modifications to the Duke criteria for the clinical diagnosis of native valve and prosthetic valve endocarditis: analysis of 118 pathologically proven cases. Clin Infect Dis 25:713–719CrossRefGoogle Scholar
  15. Lefort A, Lortholary O, Casassus P, Selton-Suty C, Guillevin L, Mainardi JL, beta-Hemolytic Streptococci Infective Endocarditis Study Group (2002) Comparison between adult endocarditis due to beta-hemolytic streptococci (serogroups A, B, C, and G) and Streptococcus milleri: a multicenter study in France. Arch Intern Med 162:2450–2456CrossRefGoogle Scholar
  16. Leung DY, Cranney GB, Hopkins AP, Walsh WF (1994) Role of transoesophageal echocardiography in the diagnosis and management of aortic root abscess. Br Heart J 72:175–181CrossRefGoogle Scholar
  17. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T et al (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30:633–638CrossRefGoogle Scholar
  18. Moet GJ, Dowzicky MJ, Jones RN (2007) Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci. Diagn Microbiol Infect Dis 57:333–336CrossRefGoogle Scholar
  19. Moreillon P, Que YA (2004) Infective endocarditis. Lancet 363:139–149CrossRefGoogle Scholar
  20. Paul-Ehrlich-Gesellschaft (2010) Empfehlungen zur kalkulierten parenteralen Initialtherapie bei Erwachsenen- Update 2010. http://www.p-e-g.org/aktuelles/435, Zugegriffen am: 06.01.2019
  21. Sambola A, Miro JM, Tornos MP, Almirante B, Moreno-Torrico A, Gurgui M et al (2002) Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature, 1962–1998. Clin Infect Dis 34:1576–1584CrossRefGoogle Scholar
  22. San Román JA, López J, Vilacosta I, Luaces M, Sarriá C, Revilla A et al (2007) Prognostic stratification of patients with left-sided endocarditis determined at admission. Am J Med 120:369.e1–369.e7CrossRefGoogle Scholar
  23. Venditti M, Tarasi A, Capone A, Galié M, Menichetti F, Martino P, Serra P (1997) Teicoplanin in the treatment of enterococcal endocarditis: clinical and microbiological study. J Antimicrob Chemother 40:449–452CrossRefGoogle Scholar
  24. Vongpatanasin W, Hillis LD, Lange RA (1996) Prosthetic heart valves. N Engl J Med 335:407–416CrossRefGoogle Scholar
  25. Wilson AP, Gaya H (1996) Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. J Antimicrob Chemother 38:507–521CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2020

Authors and Affiliations

  1. 1.Division Medizinische Mikrobiologie, Universitätsinstitut für Medizinisch Chemische Labordiagnostik der Paracelsus Medizinischen Privatuniversität SalzburgUniversitätsklinikum der Paracelsus Medizinischen Privatuniversität SalzburgSalzburgÖsterreich

Personalised recommendations